Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interferon beta in multiple sclerosis.

Literature DB >> 8916730

Interferon beta in multiple sclerosis.

R G Richards.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 1996 PMID： 8916730 PMCID： PMC2352529 DOI： 10.1136/bmj.313.7066.1159

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

5 in total

1. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

Authors:
Journal: Neurology Date: 1995-07 Impact factor: 9.910

2. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors: K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal: Neurology Date: 1995-07 Impact factor: 9.910

3. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Authors: D W Paty; D K Li
Journal: Neurology Date: 1993-04 Impact factor: 9.910

4. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors: J F Kurtzke
Journal: Neurology Date: 1983-11 Impact factor: 9.910

5. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422

5 in total

4 in total

Interferon beta in multiple sclerosis.

1. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

2. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

3. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

4. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

5. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1. Linking health technology assessment to practice. Interview by Abi Berger.

2. The need for pharmacoeconomic evaluations in the NHS.

3. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

4. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.